CN101336913A - 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物 - Google Patents

具有预防或改善脑功能降低引起的症状或疾病的作用的组合物 Download PDF

Info

Publication number
CN101336913A
CN101336913A CNA200810131360XA CN200810131360A CN101336913A CN 101336913 A CN101336913 A CN 101336913A CN A200810131360X A CNA200810131360X A CN A200810131360XA CN 200810131360 A CN200810131360 A CN 200810131360A CN 101336913 A CN101336913 A CN 101336913A
Authority
CN
China
Prior art keywords
fatty acid
acid
arachidonic
triglyceride
arachidonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200810131360XA
Other languages
English (en)
Chinese (zh)
Inventor
秋元健吾
河岛洋
小野佳子
冈市广成
冈市洋子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19066953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101336913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of CN101336913A publication Critical patent/CN101336913A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CNA200810131360XA 2001-08-02 2002-01-29 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物 Pending CN101336913A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001235519A JP2003048831A (ja) 2001-08-02 2001-08-02 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP235519/2001 2001-08-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028192125A Division CN1561206A (zh) 2001-08-02 2002-01-29 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物

Publications (1)

Publication Number Publication Date
CN101336913A true CN101336913A (zh) 2009-01-07

Family

ID=19066953

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200810131360XA Pending CN101336913A (zh) 2001-08-02 2002-01-29 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物
CNA028192125A Pending CN1561206A (zh) 2001-08-02 2002-01-29 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028192125A Pending CN1561206A (zh) 2001-08-02 2002-01-29 具有预防或改善脑功能降低引起的症状或疾病的作用的组合物

Country Status (13)

Country Link
US (1) US10744146B2 (enExample)
EP (1) EP1419768B1 (enExample)
JP (1) JP2003048831A (enExample)
KR (2) KR101989390B1 (enExample)
CN (2) CN101336913A (enExample)
AT (1) ATE520395T1 (enExample)
AU (1) AU2008201045B2 (enExample)
CA (1) CA2456049C (enExample)
CY (1) CY1111808T1 (enExample)
DK (1) DK1419768T3 (enExample)
ES (1) ES2369074T3 (enExample)
PT (1) PT1419768E (enExample)
WO (1) WO2003013497A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2004028529A1 (en) * 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
CN101843610A (zh) * 2003-03-27 2010-09-29 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
AU2004223980B2 (en) 2003-03-27 2010-11-11 Suntory Holdings Limited Lipid-improving agent and composition containing lipid-improving agent
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
FI20060154A7 (fi) * 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
GB0319358D0 (en) * 2003-08-18 2003-09-17 Btg Int Ltd Treatment of neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
US20090215896A1 (en) * 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
CN1954079B (zh) 2004-03-01 2012-08-08 三得利控股株式会社 含有作为构成要素的长链高不饱和脂肪酸的磷脂质的制造方法及其应用
CA2575671C (en) 2004-08-12 2013-10-22 Suntory Limited Method for polyunsaturated fatty acid production using novel cell preservation technique
JP4993852B2 (ja) * 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4849806B2 (ja) 2005-02-08 2012-01-11 日本水産株式会社 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法
US8241868B2 (en) 2005-02-08 2012-08-14 Nippon Suisan Kaisha, Ltd. Production of polyunsaturated fatty acids using cell treatment method
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
AU2006299665B2 (en) * 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
DE102005058369A1 (de) * 2005-12-06 2007-06-14 Lts Lohmann Therapie-Systeme Ag Ungesättigte Fettsäuren als Thrombin-Inhibitoren
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
KR20090003148A (ko) * 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
KR101430214B1 (ko) * 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
JP2009019025A (ja) * 2007-07-13 2009-01-29 Suntory Ltd 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤
AU2008282130B2 (en) 2007-07-31 2014-08-21 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2303036A1 (en) 2008-07-03 2011-04-06 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
JP2009219500A (ja) * 2009-06-22 2009-10-01 Suntory Holdings Ltd 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2011136948A (ja) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd うつ病又はうつ状態の予防又は治療用油脂組成物
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
JP6095615B2 (ja) * 2014-07-22 2017-03-15 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
CN114304375A (zh) 2015-02-11 2022-04-12 阿克海洋生物南极股份公司 脂质组合物
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
JP2016172770A (ja) * 2016-06-29 2016-09-29 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US10456368B2 (en) 2016-09-26 2019-10-29 Garrett E. Wdowin Compositions for mitigating brain trauma and methods thereof
CN110747239B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位ARA的微生物油脂及其制备方法和应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB111282A (en) 1916-11-10 Ets De Dion Bouton Improvements in or relating to Roller Bearings.
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPS63297342A (ja) 1987-05-28 1988-12-05 Nisshin Oil Mills Ltd:The 合成油脂ならびにこれを含有する脂肪乳剤輸液および経腸栄養剤
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
CA2596241C (en) 1993-06-09 2011-04-19 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
ES2118629T3 (es) 1994-10-05 1998-09-16 Milupa Gmbh & Co Kg Mezcla de grasas conteniendo fosfolipidos con acidos grasos lcp
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
EP0831805A1 (en) 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP4034370B2 (ja) * 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
KR100255868B1 (ko) * 1997-06-28 2000-05-01 김영환 2의 보수 복소수 곱셈기
EP0893064B1 (fr) 1997-07-22 2003-01-15 Societe Des Produits Nestle S.A. Composition lipidique pour formule infantile et procédé de préparation
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
ES2284286T5 (es) * 1998-10-15 2011-01-03 Dsm Ip Assets B.V. Suplementos de pufa.
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
AU2001269375A1 (en) 2000-05-08 2001-11-20 Forskarpatent I Syd Ab Anandamide and structurally related lipids as vanilloid receptor modulators
US20020077355A1 (en) 2000-05-30 2002-06-20 Liao James K. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
EP1292288B1 (en) 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
WO2002019839A1 (en) 2000-09-07 2002-03-14 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
EP1239022B1 (fr) 2001-03-09 2009-05-06 Societe Des Produits Nestle S.A. Huile contenant un ou des acide(s) gras polyinsaturé(s) à longue chaîne issus de biomasse, procédé de Préparation, allment, composition nutritionnelle, cosmétique ou pharmaceutique la contenant
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
DK1997498T3 (da) 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
CA2452401C (en) 2001-07-02 2013-02-26 Suntory Limited Process for producing fat comprising triglyceride containing highly unsaturated fatty acid
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1501493B1 (en) 2002-05-03 2009-10-07 Pronova BioPharma Norge AS Use of epa and dha in secondary prevention of strokes
AU2003260967B2 (en) 2002-09-13 2009-12-10 Suntory Holdings Limited Process for production of transesterified oils/fats or triglycerides
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
WO2004028529A1 (en) 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
CN101843610A (zh) 2003-03-27 2010-09-29 三得利控股株式会社 花生四烯酸在制备具有使超昼夜节律正常化作用的组合物中的用途
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20090215896A1 (en) 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Also Published As

Publication number Publication date
EP1419768B1 (en) 2011-08-17
CN1561206A (zh) 2005-01-05
KR20040026697A (ko) 2004-03-31
ATE520395T1 (de) 2011-09-15
US20040266874A1 (en) 2004-12-30
US10744146B2 (en) 2020-08-18
WO2003013497A1 (en) 2003-02-20
CA2456049C (en) 2012-10-16
ES2369074T3 (es) 2011-11-25
EP1419768A4 (en) 2005-07-06
PT1419768E (pt) 2011-10-13
CY1111808T1 (el) 2015-10-07
JP2003048831A (ja) 2003-02-21
KR101989390B1 (ko) 2019-06-14
CA2456049A1 (en) 2003-02-20
AU2008201045B2 (en) 2011-02-17
AU2008201045A1 (en) 2008-04-03
EP1419768A1 (en) 2004-05-19
DK1419768T3 (da) 2011-09-12
KR20170109693A (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
US10744146B2 (en) Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
CN100418519C (zh) 用于增强认知能力的含有花生四烯酸或其与二十二碳六烯酸的组合的组合物
AU2005283696B2 (en) Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases
JP4633048B2 (ja) 日内リズム正常化組成物
AU2005283697B9 (en) Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
CN105106191B (zh) 对白天活动量减少及/或抑郁症状具有改善作用的组合物
TWI445528B (zh) The use of arachidonic acid as a constituent fatty acid triglyceride for the manufacture of a pharmaceutical composition and a food product for preventing or ameliorating a symptom or a disease caused by aging of the blood vessel caused by a decrease in blood vessel elasticity, The manufacturing method
JP5496163B2 (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SUNTORY HOLDINGS CO., LTD.

Free format text: FORMER OWNER: SUNTORY LTD.

Effective date: 20090703

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090703

Address after: Osaka Japan

Applicant after: Suntory Holdings Limited

Address before: Osaka Japan

Applicant before: Suntory Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20090107